• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia.

作者信息

Mora Barbara, Giorgino Toni, Guglielmelli Paola, Rumi Elisa, Maffioli Margherita, Rambaldi Alessandro, Caramella Marianna, Komrokji Rami, Gotlib Jason, Kiladjian Jean Jacques, Cervantes Francisco, Devos Timothy, Palandri Francesca, De Stefano Valerio, Ruggeri Marco, Silver Richard T, Benevolo Giulia, Albano Francesco, Cavalloni Chiara, Barraco Daniela, Pietra Daniela, Barbui Tiziano, Rotunno Giada, Vannucchi Alessandro Maria, Passamonti Francesco

机构信息

Hematology, Department of Medicine and Surgery, University of Insubria, Ospedale di Circolo, ASST Sette Laghi, Varese, Italy.

Biophysics Institute, National Research Council of Italy, c/o Department of Biosciences, University of Milan, via Celoria 26, I-20133 Milan, Italy.

出版信息

Leuk Res. 2018 Jun;69:100-102. doi: 10.1016/j.leukres.2018.04.012. Epub 2018 Apr 23.

DOI:10.1016/j.leukres.2018.04.012
PMID:29734070
Abstract
摘要

相似文献

1
Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia.真性红细胞增多症后和原发性血小板增多症后骨髓纤维化患者的表型变异性与从真性红细胞增多症和原发性血小板增多症进展的时间相关。
Leuk Res. 2018 Jun;69:100-102. doi: 10.1016/j.leukres.2018.04.012. Epub 2018 Apr 23.
2
Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.真性红细胞增多症、原发性血小板增多症以及原发性骨髓纤维化伴或不伴JAK2 V617F突变时的巨核细胞形态及临床参数
Arch Pathol Lab Med. 2014 Sep;138(9):1203-9. doi: 10.5858/arpa.2013-0018-OA.
3
Application of current prognostic models for primary myelofibrosis in the setting of post-polycythemia vera or post-essential thrombocythemia myelofibrosis.当前原发性骨髓纤维化预后模型在真性红细胞增多症后或原发性血小板增多症后骨髓纤维化中的应用。
Leukemia. 2017 Dec;31(12):2851-2852. doi: 10.1038/leu.2017.268. Epub 2017 Aug 18.
4
The platelet-cancer loop in myeloproliferative cancer. Is thrombocythemia an enhancer of cancer invasiveness and metastasis in essential thrombocythemia, polycythemia vera and myelofibrosis?骨髓增殖性癌症中的血小板-癌症循环。在原发性血小板增多症、真性红细胞增多症和骨髓纤维化中，血小板增多症是癌症侵袭和转移的增强因素吗？
Leuk Res. 2014 Oct;38(10):1230-6. doi: 10.1016/j.leukres.2014.07.006. Epub 2014 Jul 22.
5
[Megakaryoblastic transformation in polycythemia vera--a case of megakaryoblastic leukemia associated with myelofibrosis and elevation of serum PDGF-like activity].
Rinsho Ketsueki. 1986 Nov;27(11):2118-23.
6
Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis.原发性血小板增多症后和真性红细胞增多症后的患者与原发性骨髓纤维化患者有所不同。
Leuk Res. 2017 Aug;59:110-116. doi: 10.1016/j.leukres.2017.06.001. Epub 2017 Jun 2.
7
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project.真性红细胞增多症后和原发性血小板增多症后骨髓纤维化中细胞遗传学异常的价值：MYSEC项目研究
Haematologica. 2018 Sep;103(9):e392-e394. doi: 10.3324/haematol.2017.185751. Epub 2018 Apr 5.
8
Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).慢性骨髓增殖性疾病（MPD）、原发性血小板增多症（ET）、真性红细胞增多症（PV）和慢性特发性骨髓纤维化（CIMF）的现行诊断标准。
Pathol Biol (Paris). 2007 Mar;55(2):92-104. doi: 10.1016/j.patbio.2006.06.002. Epub 2006 Aug 21.
9
Discrepancies of applying primary myelofibrosis prognostic scores for patients with post polycythemia vera/essential thrombocytosis myelofibrosis.真性红细胞增多症/原发性血小板增多症后骨髓纤维化患者应用原发性骨髓纤维化预后评分的差异。
Haematologica. 2016 Oct;101(10):e405-e406. doi: 10.3324/haematol.2016.149013. Epub 2016 Jun 27.
10
The role of beta-catenin in chronic myeloproliferative disorders.β-连环蛋白在慢性骨髓增殖性疾病中的作用。
Hum Pathol. 2008 Oct;39(10):1454-8. doi: 10.1016/j.humpath.2008.02.007. Epub 2008 Jul 11.

引用本文的文献

1
Impact of treatment for adolescent and young adults with essential thrombocythemia and polycythemia vera.治疗对青少年及年轻成人原发性血小板增多症和真性红细胞增多症的影响。
Leukemia. 2025 May;39(5):1135-1145. doi: 10.1038/s41375-025-02545-2. Epub 2025 Mar 12.
2
Prognostic and Predictive Models in Myelofibrosis.骨髓纤维化的预后和预测模型。
Curr Hematol Malig Rep. 2024 Oct;19(5):223-235. doi: 10.1007/s11899-024-00739-6. Epub 2024 Aug 24.
3
Incidence of blast phase in myelofibrosis according to anemia severity.根据贫血严重程度划分的骨髓纤维化急变期发生率。
EJHaem. 2023 Jul 17;4(3):679-689. doi: 10.1002/jha2.745. eCollection 2023 Aug.
4
Towards a Personalized Definition of Prognosis in Philadelphia-Negative Myeloproliferative Neoplasms.迈向个体化定义费城阴性骨髓增殖性肿瘤的预后。
Curr Hematol Malig Rep. 2022 Oct;17(5):127-139. doi: 10.1007/s11899-022-00672-6. Epub 2022 Sep 1.
5
Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients.预测真性红细胞增多症后和特发性血小板增多症后骨髓纤维化中的血栓形成：一项对 1258 例患者的研究。
Leukemia. 2022 Oct;36(10):2453-2460. doi: 10.1038/s41375-022-01673-3. Epub 2022 Aug 30.
6
Myelofibrotic and leukemic transformation in 2016 WHO-defined Philadelphia-negative myeloproliferative neoplasm.2016年世界卫生组织定义的费城阴性骨髓增殖性肿瘤中的骨髓纤维化和白血病转化
Blood Res. 2022 Mar 31;57(1):59-68. doi: 10.5045/br.2021.2021209.
7
Progression in Ph-Chromosome-Negative Myeloproliferative Neoplasms: An Overview on Pathologic Issues and Molecular Determinants.费城染色体阴性骨髓增殖性肿瘤的进展：病理问题与分子决定因素概述
Cancers (Basel). 2021 Nov 4;13(21):5531. doi: 10.3390/cancers13215531.
8
Standard care and investigational drugs in the treatment of myelofibrosis.骨髓纤维化治疗中的标准护理与研究性药物。
Drugs Context. 2019 Sep 26;8:212603. doi: 10.7573/dic.212603. eCollection 2019.
9
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients.原发性骨髓纤维化中真性红细胞增多症和原发性血小板增多症后的第二原发性恶性肿瘤：对 2233 例患者的研究。
Cancer Med. 2019 Aug;8(9):4089-4092. doi: 10.1002/cam4.2107. Epub 2019 Jun 7.